We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MANU:NYSEManchester Analysis

Data as of 2026-06-10 - not real-time

$22.61

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Manchester United plc is trading at $22.61, comfortably above its 20‑day SMA of 20.63 and the 50‑day SMA of 18.92, confirming a bullish price trend. The 20‑day SMA also sits above the 200‑day SMA of 17.10, reinforcing the medium‑term uptrend. Momentum indicators are supportive, with an RSI of 63 indicating strength without being overbought and a bullish MACD histogram of 0.12. Volume is on an increasing trend, and the stock is holding above its nearest support at $18.43 while still below the resistance near $24.22, suggesting upside potential. The 30‑day volatility is high at roughly 64%, reflecting sizable price swings that could amplify short‑term moves.
Fundamentally, the club posted a revenue increase of 18% and maintains an impressive gross margin of 83%, yet profitability remains a concern with a negative profit margin and a ROE of –9.6%. Debt is substantial at $756 M, driving a debt‑to‑equity ratio over 400, and cash generation is modest, with free cash flow barely above $2 M. The forward PE of 154 vastly exceeds the industry average of 17, indicating significant overvaluation. Recent Q3 results beat expectations, delivering an adjusted EPS of £0.03 and propelling the share price up 7.6% in pre‑market trading, providing a short‑term catalyst despite the broader financial headwinds.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 8/10

Key Factors

  • Bullish technicals (SMA alignment, MACD, RSI)
  • Earnings beat and strong pre‑market price reaction
  • Increasing volume supporting momentum

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • High valuation relative to peers
  • Weak profitability and high leverage
  • Continued revenue growth but limited cash conversion

Long Term

> 3 years
Cautious
Model confidence: 5/10

Key Factors

  • Severe overvaluation (forward PE ~154)
  • Elevated debt burden and negative ROE
  • Volatile earnings and limited dividend upside

Key Metrics & Analysis

Financial Health

Revenue Growth18.00%
Profit Margin-2.65%
P/E Ratio154.2
ROE-9.62%
ROA0.02%
Debt/Equity421.36
P/B Ratio15.4
Op. Cash Flow$114.9M
Free Cash Flow$2.4M
Industry P/E17.0

Technical Analysis

TrendBullish
RSI63.5
Support$18.43
Resistance$24.22
MA 20$20.63
MA 50$18.92
MA 200$17.10
MACDBullish
VolumeIncreasing
Fear & Greed Index84.27

Valuation

Target Price$25.88
Upside/Downside14.46%
GradeOvervalued
TypeBlend

Risk Assessment

Beta-0.01
Volatility63.99%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.